TriSalus Life Sciences, Inc./$TLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Ticker
$TLSI
Sector
Primary listing
Employees
102
Headquarters
Website
TLSI Metrics
BasicAdvanced
$239m
-
-$1.30
0.56
-
Price and volume
Market cap
$239m
Beta
0.56
52-week high
$7.95
52-week low
$2.20
Average daily volume
641k
Financial strength
Current ratio
5.781
Quick ratio
5.241
Long term debt to equity
267.58
Total debt to equity
269.282
Interest coverage (TTM)
-4.86%
Profitability
EBITDA (TTM)
-27.439
Gross margin (TTM)
85.07%
Net profit margin (TTM)
-60.85%
Operating margin (TTM)
-62.45%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-35.17%
Return on equity (TTM)
253.33%
Valuation
Price to revenue (TTM)
3.8
Price to book
18.65
Price to tangible book (TTM)
18.65
Price to free cash flow (TTM)
-8.403
Free cash flow yield (TTM)
-11.90%
Free cash flow per share (TTM)
-0.463
Growth
Revenue change (TTM)
39.64%
Earnings per share change (TTM)
14.20%
3-year revenue growth (CAGR)
51.09%
3-year earnings per share growth (CAGR)
-66.57%
TLSI News
AllArticlesVideos
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·2 weeks ago
TLSI ALERT: Levi & Korsinsky Investigates TriSalus Life Sciences, Inc. on Behalf of Shareholders Who Lost Money
Newsfile Corp·3 weeks ago
Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky Today
Newsfile Corp·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs